Global Prostate Cancer Diagnosis & Treatment Market Research and Analysis 2015-2022
Market Insights
The Global Prostate Cancer Market is expected to grow at the CAGR of 10.2 % during 2017-2022. The market is growing impressively due to rise in incidence and prevalence rate of prostate cancer, robust R&D exploration and rising investment in grants and investment across the globe. Prostate cancer is an androgen-dependent disease that responds to medicine and treatment in the initial stages, however in the later stages it becomes resistant to therapies and other treatments. There are certain risk and causes of prostate cancer which includes age, ethnicity, family history and genes, being overweight or obese, IGF-1 (Insulin like growth factor), vasectomy, inflammation of the prostate and so on. Prostate cancer results into abnormal and uncontrolled growth of cells in prostate gland of men. It majorly affects men of developed region with age 50 and above. The U.S. contributes highest in prostate cancer market due to prevalence of prostate cancer and adoption of innovative surgeries and treatments. According to WHO, in 2012 more than 14 million new cases of cancer and 8.2 million cancer fatalities were registered. The trend is expected to continue with new cases to increase over 70%. Early diagnosis, innovative treatment methods and quality care of the patients may enable to survive prostate cancer patients.
Global rise in prostate cancer and adoption of minimally invasive surgeries are driving the market growth across the globe. There are other factors that are boosting the market growth of Global Prostate Cancer Market it includes R&D, rise in grants and funding, increasing adoption of personalized medicines, growing pharmaceutical industries and so on. Rising diagnostic centers across the globe, investment from government and private players have bolstered the market growth. Successful clinical trials and FDA approval will influence the prostate cancer market in near future.
Geographical Insights
North America and Europe has considerable contribution in the growth of Global Prostate Cancer Market followed by APAC region. The key driving forces includes rising incidence and prevalence of prostate cancer and adoption of innovative surgeries and treatment across the globe. Emerging economies such as China, India, Japan and Korea have huge population of cancer patients. Technological advancement, innovation and improved healthcare spending will drive the APAC region. Improved standard of living, infrastructural development and favorable government policies are some other factors that will boost prostate cancer market in APAC region.
Competitive Insights
Some of the key players contributing significantly in the growth of prostate cancer market includes Abbott Laboratories, Abbvie, Johnson & Johnson, AstraZeneca Plc, Astellas Pharma, Inc., Sanofi, Medivation, Inc., Ipsen SA and Bayer Healthcare Pharmaceutical, Inc. Prostate cancer market companies are constantly focusing on product launch, R&D, partnerships, M&A, innovation and technological advancement. The report also includes detailed market overview, strategic recommendations, key company analysis, key findings, analyst insights, predictive analysis, pipeline analysis, market determinants, market segmentation, geographical analysis, company profiling of the market.
Market Segmentation
The Global Prostate Cancer Market is expected to grow at the CAGR of 10.2 % during 2017-2022. The market is growing impressively due to rise in incidence and prevalence rate of prostate cancer, robust R&D exploration and rising investment in grants and investment across the globe. Prostate cancer is an androgen-dependent disease that responds to medicine and treatment in the initial stages, however in the later stages it becomes resistant to therapies and other treatments. There are certain risk and causes of prostate cancer which includes age, ethnicity, family history and genes, being overweight or obese, IGF-1 (Insulin like growth factor), vasectomy, inflammation of the prostate and so on. Prostate cancer results into abnormal and uncontrolled growth of cells in prostate gland of men. It majorly affects men of developed region with age 50 and above. The U.S. contributes highest in prostate cancer market due to prevalence of prostate cancer and adoption of innovative surgeries and treatments. According to WHO, in 2012 more than 14 million new cases of cancer and 8.2 million cancer fatalities were registered. The trend is expected to continue with new cases to increase over 70%. Early diagnosis, innovative treatment methods and quality care of the patients may enable to survive prostate cancer patients.
Global rise in prostate cancer and adoption of minimally invasive surgeries are driving the market growth across the globe. There are other factors that are boosting the market growth of Global Prostate Cancer Market it includes R&D, rise in grants and funding, increasing adoption of personalized medicines, growing pharmaceutical industries and so on. Rising diagnostic centers across the globe, investment from government and private players have bolstered the market growth. Successful clinical trials and FDA approval will influence the prostate cancer market in near future.
Geographical Insights
North America and Europe has considerable contribution in the growth of Global Prostate Cancer Market followed by APAC region. The key driving forces includes rising incidence and prevalence of prostate cancer and adoption of innovative surgeries and treatment across the globe. Emerging economies such as China, India, Japan and Korea have huge population of cancer patients. Technological advancement, innovation and improved healthcare spending will drive the APAC region. Improved standard of living, infrastructural development and favorable government policies are some other factors that will boost prostate cancer market in APAC region.
Competitive Insights
Some of the key players contributing significantly in the growth of prostate cancer market includes Abbott Laboratories, Abbvie, Johnson & Johnson, AstraZeneca Plc, Astellas Pharma, Inc., Sanofi, Medivation, Inc., Ipsen SA and Bayer Healthcare Pharmaceutical, Inc. Prostate cancer market companies are constantly focusing on product launch, R&D, partnerships, M&A, innovation and technological advancement. The report also includes detailed market overview, strategic recommendations, key company analysis, key findings, analyst insights, predictive analysis, pipeline analysis, market determinants, market segmentation, geographical analysis, company profiling of the market.
Market Segmentation
- Global Prostate Cancer Market Research And Analysis, By Diagnostic Techniques
- Global Prostate Cancer Market Research And Analysis, By Radiation Therapy
- Global Prostate Cancer Market Research And Analysis, By Surgery
- Global Prostate Cancer Market Research And Analysis, By Chemotherapy
- Comprehensive research methodology of Global Prostate Cancer Market.
- This report also includes detailed and extensive market overview with current market recommendations & key analysts insights.
- Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the Global Prostate Cancer Market.
- Insights about market determinants which are stimulating the Global Prostate Cancer Market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
REPORT SUMMARY
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
1.2.4. EXCEPTIONS
MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.3. CURRENT MARKET TRENDS & ANALYST INSIGHT
2.3.1. KEY FINDINGS
2.3.2. RECOMMENDATION
2.3.3. CONCLUSION
2.4. PIPELINE ANALYSIS
2.5. REGULATION
MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. RISE IN INCIDENCE & PREVALENCE RATE OF CANCER DISEASES
3.1.2. GROWING INVESTMENT AND GRANTS FROM GOVERNMENT AND PRIVATE PLAYERS
3.1.3. INCREASING OBESE AND OVER-WEIGHT POPULATION ACROSS THE GLOBE
3.1.4. RESEARCH & DEVELOPMENT IN PROSTATE CANCER MARKET
3.1.5. RISING ADOPTION OF PERSONALIZED MEDICINES
3.1.6. TECHNOLOGICAL ADVANCEMENT AND INNOVATION
3.2. RESTRAINT
3.2.1. HIGH COST OF GLOBAL PROSTATE CANCER DRUGS AND SURGERIES
3.2.2. REIMBURSEMENT POLICIES MAY AFFECT THE GROWTH OF THE MARKET
3.2.3. SURGICAL RISKS AND SIDE EFFECTS
3.3. OPPORTUNITY
3.3.1. UNTAPPED APAC REGION HAVE HUGE OPPORTUNITY FOR GLOBAL PROSTATE CANCER MARKET
3.3.2. SUCCESSFUL CLINICAL TRIALS AND FDA APPROVALS
3.3.3. RISE IN DIAGNOSTIC CENTERS ACROSS THE GLOBE
3.3.4. GROWTH IN PHARMACEUTICAL MARKET OF PROSTATE CANCER
MARKET SEGMENTATION
4.1. GLOBAL PROSTATE CANCER MARKET RESEARCH AND ANALYSIS, BY DIAGNOSTIC TECHNIQUES
4.1.1. PROSTATE SPECIFIC ANTIGEN TEST (PSA)
4.1.2. DIGITAL RECTAL EXAM (DRE)
4.2. GLOBAL PROSTATE CANCER MARKET RESEARCH AND ANALYSIS, BY RADIATION THERAPY
4.2.1. BRACHYTHERAPY
4.2.1.1. TEMPORARY BRACHYTHERAPY
4.2.1.2. PERMANENT BRACHYTHERAPY
4.2.2. EXTERNAL BEAM RADIATION THERAPY
4.2.2.1. STEREOTACTIC BODY RADIATION THERAPY
4.2.2.2. PROTON BEAM RADIATION THERAPY
4.2.2.3. 3D CONFORMAL RADIATION THERAPY
4.2.2.4. INTENSITY MODULATED RADIATION THERAPY
4.3. DIGITAL RECTAL EXAM (DRE) GLOBAL PROSTATE CANCER MARKET RESEARCH AND ANALYSIS, BY SURGERY
4.3.1. RADICAL PROSTATECTOMY
4.3.2. TRANS URETHRAL RESECTION (TUR)
4.3.3. ORCHIDECTOMY
4.4. DIGITAL RECTAL EXAM (DRE) GLOBAL PROSTATE CANCER MARKET RESEARCH AND ANALYSIS, BY CHEMOTHERAPY
4.4.1. DOCETAXEL
4.4.2. VINORELBINE
4.4.3. CARBOPLATIN
4.4.4. ETOPOSIDE
4.4.5. VINBLASTINE
COMPETITIVE LANDSCAPE
5.1. KEY STRATEGIES
5.2. KEY COMPANY ANALYSIS
REGIONAL ANALYSIS
6.1. NORTH AMERICAN MARKET
6.1.1. UNITED STATES
6.1.1.1. CANADA
6.1.1.2. REST OF NORTH AMERICA
6.1.2. EUROPEAN MARKET
6.1.2.1. UK
6.1.2.2. GERMANY
6.1.2.3. SPAIN
6.1.2.4. FRANCE
6.1.2.5. ITALY
6.1.2.6. REST OF EUROPE
6.1.3. ASIA PACIFIC MARKET
6.1.3.1. INDIA
6.1.3.2. CHINA
6.1.3.3. JAPAN
6.1.3.4. REST OF ASIA PACIFIC
6.1.4. REST OF THE WORLD
COMPANY PROFILES
7.1. ABBOTT LABORATORIES
7.1.1. INTRODUCTION
7.1.2. ABBOTT LABORATORIES PRODUCT PORTFOLIO
7.1.3. ABBOTT LABORATORIES RECENT ACTIVITIES
7.2. ABBVIE
7.2.1. INTRODUCTION
7.2.2. ABBVIE PRODUCT PORTFOLIO
7.2.3. ABBVIE RECENT ACTIVITIES
7.3. ACTIVE BIOTECH
7.3.1. INTRODUCTION
7.3.2. ACTIVE BIOTECH PRODUCT PORTFOLIO
7.3.3. ACTIVE BIOTECH RECENT ACTIVITIES
7.4. AMGEN
7.4.1. INTRODUCTION
7.4.2. AMGEN PRODUCT PORTFOLIO
7.4.3. AMGEN RECENT ACTIVITIES
7.5. ASTELLAS PHARMA INC
7.5.1. INTRODUCTION
7.5.2. ASTELLAS PHARMA INC PRODUCT PORTFOLIO
7.5.3. ASTELLAS PHARMA INC RECENT ACTIVITIES
7.6. ASTRAZENECA
7.6.1. INTRODUCTION
7.6.2. ASTRAZENECA PRODUCT PORTFOLIO
7.6.3. ASTRAZENECA RECENT ACTIVITIES
7.6.4. ASTRAZENECA SWOTANALYSIS
7.7. BAVARIAN NORDIC
7.7.1. INTRODUCTION
7.7.2. BAVARIAN NORDIC PRODUCT PORTFOLIO
7.7.3. BAVARIAN NORDIC RECENT ACTIVITIES
7.8. BAYER
7.8.1. INTRODUCTION
7.8.2. BAYER PRODUCT PORTFOLIO
7.8.3. BAYER RECENT ACTIVITIES
7.9. BRISTOL-MYERS SQUIBB
7.9.1. INTRODUCTION
7.9.2. BRISTOL-MYERS SQUIBB PRODUCT PORTFOLIO
7.9.3. BRISTOL-MYERS SQUIBB RECENT ACTIVITIES
7.10. DENDREON
7.10.1. INTRODUCTION
7.10.2. DENDREON PRODUCT PORTFOLIO
7.10.3. DENDREON RECENT ACTIVITIES
7.11. ENDO PHARMACEUTICALS INC (INDEVUS PHARMACEUTICALS INC)
7.11.1. INTRODUCTION
7.11.2. ENDO PHARMACEUTICALS INC (INDEVUS PHARMACEUTICALS INC) PRODUCT PORTFOLIO
7.11.3. ENDO PHARMACEUTICALS INC (INDEVUS PHARMACEUTICALS INC) RECENT ACTIVITIES
7.12. FERRING PHARMACEUTICALS
7.12.1. INTRODUCTION
7.12.2. FERRING PHARMACEUTICALS PRODUCT PORTFOLIO
7.12.3. FERRING PHARMACEUTICALS RECENT ACTIVITIES
7.13. GE HEALTHCARE
7.13.1. INTRODUCTION
7.13.2. GE HEALTHCARE PRODUCT PORTFOLIO
7.13.3. GE HEALTHCARE RECENT ACTIVITIES
7.14. GLAXOSMITHKLINE
7.14.1. INTRODUCTION
7.14.2. GLAXOSMITHKLINE PRODUCT PORTFOLIO
7.14.3. GLAXOSMITHKLINE RECENT ACTIVITIES
7.15. IPSEN
7.15.1. INTRODUCTION
7.15.2. IPSEN PRODUCT PORTFOLIO
7.15.3. IPSEN RECENT ACTIVITIES
7.16. JOHNSON & JOHNSON
7.16.1. INTRODUCTION
7.16.2. JOHNSON & JOHNSON PRODUCT PORTFOLIO
7.16.3. JOHNSON & JOHNSON RECENT ACTIVITIES
7.17. PFIZER, INC.
7.17.1. INTRODUCTION
7.17.2. PFIZER, INC. PRODUCT PORTFOLIO
7.17.3. PFIZER, INC. RECENT ACTIVITIES
7.17.4. PFIZER, INC. SWOTANALYSIS
7.18. SANOFI
7.18.1. INTRODUCTION
7.18.2. SANOFI PRODUCT PORTFOLIO
7.18.3. SANOFI RECENT ACTIVITIES
7.19. SEIMENS HEALTHCARE
7.19.1. INTRODUCTION
7.19.2. SEIMENS HEALTHCARE PRODUCT PORTFOLIO
7.19.3. SEIMENS HEALTHCARE RECENT ACTIVITIES
7.20. TAKEDA PHARMACEUTICAL CO. LTD
7.20.1. INTRODUCTION
7.20.2. TAKEDA PHARMACEUTICAL CO. LTD PRODUCT PORTFOLIO
7.20.3. TAKEDA PHARMACEUTICAL CO. LTD RECENT ACTIVITIES
7.21. TEVA PHARMACEUTICAL
7.21.1. INTRODUCTION
7.21.2. TEVA PHARMACEUTICAL PRODUCT PORTFOLIO
7.21.3. TEVA PHARMACEUTICAL RECENT ACTIVITIES
7.22. TOLMAR INC
7.22.1. INTRODUCTION
7.22.2. TOLMAR INC PRODUCT PORTFOLIO
7.22.3. TOLMAR INC RECENT ACTIVITIES
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
1.2.4. EXCEPTIONS
MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.3. CURRENT MARKET TRENDS & ANALYST INSIGHT
2.3.1. KEY FINDINGS
2.3.2. RECOMMENDATION
2.3.3. CONCLUSION
2.4. PIPELINE ANALYSIS
2.5. REGULATION
MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. RISE IN INCIDENCE & PREVALENCE RATE OF CANCER DISEASES
3.1.2. GROWING INVESTMENT AND GRANTS FROM GOVERNMENT AND PRIVATE PLAYERS
3.1.3. INCREASING OBESE AND OVER-WEIGHT POPULATION ACROSS THE GLOBE
3.1.4. RESEARCH & DEVELOPMENT IN PROSTATE CANCER MARKET
3.1.5. RISING ADOPTION OF PERSONALIZED MEDICINES
3.1.6. TECHNOLOGICAL ADVANCEMENT AND INNOVATION
3.2. RESTRAINT
3.2.1. HIGH COST OF GLOBAL PROSTATE CANCER DRUGS AND SURGERIES
3.2.2. REIMBURSEMENT POLICIES MAY AFFECT THE GROWTH OF THE MARKET
3.2.3. SURGICAL RISKS AND SIDE EFFECTS
3.3. OPPORTUNITY
3.3.1. UNTAPPED APAC REGION HAVE HUGE OPPORTUNITY FOR GLOBAL PROSTATE CANCER MARKET
3.3.2. SUCCESSFUL CLINICAL TRIALS AND FDA APPROVALS
3.3.3. RISE IN DIAGNOSTIC CENTERS ACROSS THE GLOBE
3.3.4. GROWTH IN PHARMACEUTICAL MARKET OF PROSTATE CANCER
MARKET SEGMENTATION
4.1. GLOBAL PROSTATE CANCER MARKET RESEARCH AND ANALYSIS, BY DIAGNOSTIC TECHNIQUES
4.1.1. PROSTATE SPECIFIC ANTIGEN TEST (PSA)
4.1.2. DIGITAL RECTAL EXAM (DRE)
4.2. GLOBAL PROSTATE CANCER MARKET RESEARCH AND ANALYSIS, BY RADIATION THERAPY
4.2.1. BRACHYTHERAPY
4.2.1.1. TEMPORARY BRACHYTHERAPY
4.2.1.2. PERMANENT BRACHYTHERAPY
4.2.2. EXTERNAL BEAM RADIATION THERAPY
4.2.2.1. STEREOTACTIC BODY RADIATION THERAPY
4.2.2.2. PROTON BEAM RADIATION THERAPY
4.2.2.3. 3D CONFORMAL RADIATION THERAPY
4.2.2.4. INTENSITY MODULATED RADIATION THERAPY
4.3. DIGITAL RECTAL EXAM (DRE) GLOBAL PROSTATE CANCER MARKET RESEARCH AND ANALYSIS, BY SURGERY
4.3.1. RADICAL PROSTATECTOMY
4.3.2. TRANS URETHRAL RESECTION (TUR)
4.3.3. ORCHIDECTOMY
4.4. DIGITAL RECTAL EXAM (DRE) GLOBAL PROSTATE CANCER MARKET RESEARCH AND ANALYSIS, BY CHEMOTHERAPY
4.4.1. DOCETAXEL
4.4.2. VINORELBINE
4.4.3. CARBOPLATIN
4.4.4. ETOPOSIDE
4.4.5. VINBLASTINE
COMPETITIVE LANDSCAPE
5.1. KEY STRATEGIES
5.2. KEY COMPANY ANALYSIS
REGIONAL ANALYSIS
6.1. NORTH AMERICAN MARKET
6.1.1. UNITED STATES
6.1.1.1. CANADA
6.1.1.2. REST OF NORTH AMERICA
6.1.2. EUROPEAN MARKET
6.1.2.1. UK
6.1.2.2. GERMANY
6.1.2.3. SPAIN
6.1.2.4. FRANCE
6.1.2.5. ITALY
6.1.2.6. REST OF EUROPE
6.1.3. ASIA PACIFIC MARKET
6.1.3.1. INDIA
6.1.3.2. CHINA
6.1.3.3. JAPAN
6.1.3.4. REST OF ASIA PACIFIC
6.1.4. REST OF THE WORLD
COMPANY PROFILES
7.1. ABBOTT LABORATORIES
7.1.1. INTRODUCTION
7.1.2. ABBOTT LABORATORIES PRODUCT PORTFOLIO
7.1.3. ABBOTT LABORATORIES RECENT ACTIVITIES
7.2. ABBVIE
7.2.1. INTRODUCTION
7.2.2. ABBVIE PRODUCT PORTFOLIO
7.2.3. ABBVIE RECENT ACTIVITIES
7.3. ACTIVE BIOTECH
7.3.1. INTRODUCTION
7.3.2. ACTIVE BIOTECH PRODUCT PORTFOLIO
7.3.3. ACTIVE BIOTECH RECENT ACTIVITIES
7.4. AMGEN
7.4.1. INTRODUCTION
7.4.2. AMGEN PRODUCT PORTFOLIO
7.4.3. AMGEN RECENT ACTIVITIES
7.5. ASTELLAS PHARMA INC
7.5.1. INTRODUCTION
7.5.2. ASTELLAS PHARMA INC PRODUCT PORTFOLIO
7.5.3. ASTELLAS PHARMA INC RECENT ACTIVITIES
7.6. ASTRAZENECA
7.6.1. INTRODUCTION
7.6.2. ASTRAZENECA PRODUCT PORTFOLIO
7.6.3. ASTRAZENECA RECENT ACTIVITIES
7.6.4. ASTRAZENECA SWOTANALYSIS
7.7. BAVARIAN NORDIC
7.7.1. INTRODUCTION
7.7.2. BAVARIAN NORDIC PRODUCT PORTFOLIO
7.7.3. BAVARIAN NORDIC RECENT ACTIVITIES
7.8. BAYER
7.8.1. INTRODUCTION
7.8.2. BAYER PRODUCT PORTFOLIO
7.8.3. BAYER RECENT ACTIVITIES
7.9. BRISTOL-MYERS SQUIBB
7.9.1. INTRODUCTION
7.9.2. BRISTOL-MYERS SQUIBB PRODUCT PORTFOLIO
7.9.3. BRISTOL-MYERS SQUIBB RECENT ACTIVITIES
7.10. DENDREON
7.10.1. INTRODUCTION
7.10.2. DENDREON PRODUCT PORTFOLIO
7.10.3. DENDREON RECENT ACTIVITIES
7.11. ENDO PHARMACEUTICALS INC (INDEVUS PHARMACEUTICALS INC)
7.11.1. INTRODUCTION
7.11.2. ENDO PHARMACEUTICALS INC (INDEVUS PHARMACEUTICALS INC) PRODUCT PORTFOLIO
7.11.3. ENDO PHARMACEUTICALS INC (INDEVUS PHARMACEUTICALS INC) RECENT ACTIVITIES
7.12. FERRING PHARMACEUTICALS
7.12.1. INTRODUCTION
7.12.2. FERRING PHARMACEUTICALS PRODUCT PORTFOLIO
7.12.3. FERRING PHARMACEUTICALS RECENT ACTIVITIES
7.13. GE HEALTHCARE
7.13.1. INTRODUCTION
7.13.2. GE HEALTHCARE PRODUCT PORTFOLIO
7.13.3. GE HEALTHCARE RECENT ACTIVITIES
7.14. GLAXOSMITHKLINE
7.14.1. INTRODUCTION
7.14.2. GLAXOSMITHKLINE PRODUCT PORTFOLIO
7.14.3. GLAXOSMITHKLINE RECENT ACTIVITIES
7.15. IPSEN
7.15.1. INTRODUCTION
7.15.2. IPSEN PRODUCT PORTFOLIO
7.15.3. IPSEN RECENT ACTIVITIES
7.16. JOHNSON & JOHNSON
7.16.1. INTRODUCTION
7.16.2. JOHNSON & JOHNSON PRODUCT PORTFOLIO
7.16.3. JOHNSON & JOHNSON RECENT ACTIVITIES
7.17. PFIZER, INC.
7.17.1. INTRODUCTION
7.17.2. PFIZER, INC. PRODUCT PORTFOLIO
7.17.3. PFIZER, INC. RECENT ACTIVITIES
7.17.4. PFIZER, INC. SWOTANALYSIS
7.18. SANOFI
7.18.1. INTRODUCTION
7.18.2. SANOFI PRODUCT PORTFOLIO
7.18.3. SANOFI RECENT ACTIVITIES
7.19. SEIMENS HEALTHCARE
7.19.1. INTRODUCTION
7.19.2. SEIMENS HEALTHCARE PRODUCT PORTFOLIO
7.19.3. SEIMENS HEALTHCARE RECENT ACTIVITIES
7.20. TAKEDA PHARMACEUTICAL CO. LTD
7.20.1. INTRODUCTION
7.20.2. TAKEDA PHARMACEUTICAL CO. LTD PRODUCT PORTFOLIO
7.20.3. TAKEDA PHARMACEUTICAL CO. LTD RECENT ACTIVITIES
7.21. TEVA PHARMACEUTICAL
7.21.1. INTRODUCTION
7.21.2. TEVA PHARMACEUTICAL PRODUCT PORTFOLIO
7.21.3. TEVA PHARMACEUTICAL RECENT ACTIVITIES
7.22. TOLMAR INC
7.22.1. INTRODUCTION
7.22.2. TOLMAR INC PRODUCT PORTFOLIO
7.22.3. TOLMAR INC RECENT ACTIVITIES
LIST OF TABLES
Table # 1 GLOBAL PROSTATE CANCER MARKET RESEARCH AND ANALYSIS, BY DIAGNOSTIC TECHNIQUES
Table # 2 PROSTATE SPECIFIC ANTIGEN TEST (PSA)
Table # 3 DIGITAL RECTAL EXAM (DRE)
Table # 4 GLOBAL PROSTATE CANCER MARKET RESEARCH AND ANALYSIS, BY RADIATION THERAPY
Table # 5 BRACHYTHERAPY
Table # 6 TEMPORARY BRACHYTHERAPY
Table # 7 PERMANENT BRACHYTHERAPY
Table # 8 EXTERNAL BEAM RADIATION THERAPY
Table # 9 STEREOTACTIC BODY RADIATION THERAPY
Table # 10 PROTON BEAM RADIATION THERAPY
Table # 11 3D CONFORMAL RADIATION THERAPY
Table # 12 INTENSITY MODULATED RADIATION THERAPY
Table # 13 DIGITAL RECTAL EXAM (DRE) GLOBAL PROSTATE CANCER MARKET RESEARCH AND ANALYSIS, BY SURGERY
Table # 14 RADICAL PROSTATECTOMY
Table # 15 TRANS URETHRAL RESECTION (TUR)
Table # 16 ORCHIDECTOMY
Table # 17 DIGITAL RECTAL EXAM (DRE) GLOBAL PROSTATE CANCER MARKET RESEARCH AND ANALYSIS, BY CHEMOTHERAPY
Table # 18 DOCETAXEL
Table # 19 VINORELBINE
Table # 20 CARBOPLATIN
Table # 21 ETOPOSIDE
Table # 22 VINBLASTINE
Table # 23 ABBOTT LABORATORIES PRODUCT PORTFOLIO
Table # 24 ABBOTT LABORATORIES RECENT ACTIVITIES
Table # 25 ABBVIE PRODUCT PORTFOLIO
Table # 26 ABBVIE RECENT ACTIVITIES
Table # 27 ACTIVE BIOTECH PRODUCT PORTFOLIO
Table # 28 ACTIVE BIOTECH RECENT ACTIVITIES
Table # 29 AMGEN PRODUCT PORTFOLIO
Table # 30 AMGEN RECENT ACTIVITIES
Table # 31 ASTELLAS PHARMA INC PRODUCT PORTFOLIO
Table # 32 ASTELLAS PHARMA INC RECENT ACTIVITIES
Table # 33 ASTRAZENECA PRODUCT PORTFOLIO
Table # 34 ASTRAZENECA RECENT ACTIVITIES
Table # 35 INTRODUCTION
Table # 36 BAVARIAN NORDIC PRODUCT PORTFOLIO
Table # 37 BAVARIAN NORDIC RECENT ACTIVITIES
Table # 38 BAYER PRODUCT PORTFOLIO
Table # 39 BAYER RECENT ACTIVITIES
Table # 40 BRISTOL-MYERS SQUIBB PRODUCT PORTFOLIO
Table # 41 BRISTOL-MYERS SQUIBB RECENT ACTIVITIES
Table # 42 DENDREON PRODUCT PORTFOLIO
Table # 43 DENDREON RECENT ACTIVITIES
Table # 44 ENDO PHARMACEUTICALS INC (INDEVUS PHARMACEUTICALS INC) PRODUCT PORTFOLIO
Table # 45 ENDO PHARMACEUTICALS INC (INDEVUS PHARMACEUTICALS INC) RECENT ACTIVITIES
Table # 46 FERRING PHARMACEUTICALS PRODUCT PORTFOLIO
Table # 47 FERRING PHARMACEUTICALS RECENT ACTIVITIES
Table # 48 GE HEALTHCARE PRODUCT PORTFOLIO
Table # 49 GE HEALTHCARE RECENT ACTIVITIES
Table # 50 GLAXOSMITHKLINE PRODUCT PORTFOLIO
Table # 51 GLAXOSMITHKLINE RECENT ACTIVITIES
Table # 52 IPSEN PRODUCT PORTFOLIO
Table # 53 IPSEN RECENT ACTIVITIES
Table # 54 JOHNSON & JOHNSON PRODUCT PORTFOLIO
Table # 55 JOHNSON & JOHNSON RECENT ACTIVITIES
Table # 56 PFIZER, INC. PRODUCT PORTFOLIO
Table # 57 PFIZER, INC. RECENT ACTIVITIES
Table # 58 SANOFI PRODUCT PORTFOLIO
Table # 59 SANOFI RECENT ACTIVITIES
Table # 60 SEIMENS HEALTHCARE PRODUCT PORTFOLIO
Table # 61 SEIMENS HEALTHCARE RECENT ACTIVITIES
Table # 62 TAKEDA PHARMACEUTICAL CO. LTD PRODUCT PORTFOLIO
Table # 63 TAKEDA PHARMACEUTICAL CO. LTD RECENT ACTIVITIES
Table # 64 TEVA PHARMACEUTICAL PRODUCT PORTFOLIO
Table # 65 TEVA PHARMACEUTICAL RECENT ACTIVITIES
Table # 66 TOLMAR INC PRODUCT PORTFOLIO
Table # 67 TOLMAR INC RECENT ACTIVITIES
Table # 1 GLOBAL PROSTATE CANCER MARKET RESEARCH AND ANALYSIS, BY DIAGNOSTIC TECHNIQUES
Table # 2 PROSTATE SPECIFIC ANTIGEN TEST (PSA)
Table # 3 DIGITAL RECTAL EXAM (DRE)
Table # 4 GLOBAL PROSTATE CANCER MARKET RESEARCH AND ANALYSIS, BY RADIATION THERAPY
Table # 5 BRACHYTHERAPY
Table # 6 TEMPORARY BRACHYTHERAPY
Table # 7 PERMANENT BRACHYTHERAPY
Table # 8 EXTERNAL BEAM RADIATION THERAPY
Table # 9 STEREOTACTIC BODY RADIATION THERAPY
Table # 10 PROTON BEAM RADIATION THERAPY
Table # 11 3D CONFORMAL RADIATION THERAPY
Table # 12 INTENSITY MODULATED RADIATION THERAPY
Table # 13 DIGITAL RECTAL EXAM (DRE) GLOBAL PROSTATE CANCER MARKET RESEARCH AND ANALYSIS, BY SURGERY
Table # 14 RADICAL PROSTATECTOMY
Table # 15 TRANS URETHRAL RESECTION (TUR)
Table # 16 ORCHIDECTOMY
Table # 17 DIGITAL RECTAL EXAM (DRE) GLOBAL PROSTATE CANCER MARKET RESEARCH AND ANALYSIS, BY CHEMOTHERAPY
Table # 18 DOCETAXEL
Table # 19 VINORELBINE
Table # 20 CARBOPLATIN
Table # 21 ETOPOSIDE
Table # 22 VINBLASTINE
Table # 23 ABBOTT LABORATORIES PRODUCT PORTFOLIO
Table # 24 ABBOTT LABORATORIES RECENT ACTIVITIES
Table # 25 ABBVIE PRODUCT PORTFOLIO
Table # 26 ABBVIE RECENT ACTIVITIES
Table # 27 ACTIVE BIOTECH PRODUCT PORTFOLIO
Table # 28 ACTIVE BIOTECH RECENT ACTIVITIES
Table # 29 AMGEN PRODUCT PORTFOLIO
Table # 30 AMGEN RECENT ACTIVITIES
Table # 31 ASTELLAS PHARMA INC PRODUCT PORTFOLIO
Table # 32 ASTELLAS PHARMA INC RECENT ACTIVITIES
Table # 33 ASTRAZENECA PRODUCT PORTFOLIO
Table # 34 ASTRAZENECA RECENT ACTIVITIES
Table # 35 INTRODUCTION
Table # 36 BAVARIAN NORDIC PRODUCT PORTFOLIO
Table # 37 BAVARIAN NORDIC RECENT ACTIVITIES
Table # 38 BAYER PRODUCT PORTFOLIO
Table # 39 BAYER RECENT ACTIVITIES
Table # 40 BRISTOL-MYERS SQUIBB PRODUCT PORTFOLIO
Table # 41 BRISTOL-MYERS SQUIBB RECENT ACTIVITIES
Table # 42 DENDREON PRODUCT PORTFOLIO
Table # 43 DENDREON RECENT ACTIVITIES
Table # 44 ENDO PHARMACEUTICALS INC (INDEVUS PHARMACEUTICALS INC) PRODUCT PORTFOLIO
Table # 45 ENDO PHARMACEUTICALS INC (INDEVUS PHARMACEUTICALS INC) RECENT ACTIVITIES
Table # 46 FERRING PHARMACEUTICALS PRODUCT PORTFOLIO
Table # 47 FERRING PHARMACEUTICALS RECENT ACTIVITIES
Table # 48 GE HEALTHCARE PRODUCT PORTFOLIO
Table # 49 GE HEALTHCARE RECENT ACTIVITIES
Table # 50 GLAXOSMITHKLINE PRODUCT PORTFOLIO
Table # 51 GLAXOSMITHKLINE RECENT ACTIVITIES
Table # 52 IPSEN PRODUCT PORTFOLIO
Table # 53 IPSEN RECENT ACTIVITIES
Table # 54 JOHNSON & JOHNSON PRODUCT PORTFOLIO
Table # 55 JOHNSON & JOHNSON RECENT ACTIVITIES
Table # 56 PFIZER, INC. PRODUCT PORTFOLIO
Table # 57 PFIZER, INC. RECENT ACTIVITIES
Table # 58 SANOFI PRODUCT PORTFOLIO
Table # 59 SANOFI RECENT ACTIVITIES
Table # 60 SEIMENS HEALTHCARE PRODUCT PORTFOLIO
Table # 61 SEIMENS HEALTHCARE RECENT ACTIVITIES
Table # 62 TAKEDA PHARMACEUTICAL CO. LTD PRODUCT PORTFOLIO
Table # 63 TAKEDA PHARMACEUTICAL CO. LTD RECENT ACTIVITIES
Table # 64 TEVA PHARMACEUTICAL PRODUCT PORTFOLIO
Table # 65 TEVA PHARMACEUTICAL RECENT ACTIVITIES
Table # 66 TOLMAR INC PRODUCT PORTFOLIO
Table # 67 TOLMAR INC RECENT ACTIVITIES
LIST OF FIGURES
Figure # 1 NORTH AMERICAN MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure # 2 UNITED STATES MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure # 3 CANADA MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure # 4 EUROPEAN MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure # 5 UK MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure # 6 GERMANY MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure # 7 SPAIN MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure # 8 FRANCE MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure # 9 ITALY MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure # 10 ROE MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure # 11 ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure # 12 INDIA MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure # 13 CHINA MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure # 14 JAPAN MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure # 15 ROPAC MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure # 16 REST OF THE WORLD MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure # 1 NORTH AMERICAN MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure # 2 UNITED STATES MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure # 3 CANADA MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure # 4 EUROPEAN MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure # 5 UK MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure # 6 GERMANY MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure # 7 SPAIN MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure # 8 FRANCE MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure # 9 ITALY MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure # 10 ROE MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure # 11 ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure # 12 INDIA MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure # 13 CHINA MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure # 14 JAPAN MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure # 15 ROPAC MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure # 16 REST OF THE WORLD MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
